Drug safety notice: Sarilumab – for intravenous administration in COVID-19 patients

September 10, 2021

Sarilumab is a human monoclonal antibody that specifically binds to interleukin-6 receptors and blocks the activity of pro-inflammatory cytokines. Sarilumab is typically given via the subcutaneous route, however for COVID-19 patients Sarilumab must be administered intravenously.

Note: Sarilumab is ONLY to be administered by nurses who are trained to administer monoclonal antibodies.

For further details please see Sarilumab information sheet.

For more information please contact the pharmacy department on ext. 5263/3783.